Sysmex Corp is primarily active in the healthcare and medical technology industries.

The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).

Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.

Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.

Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.

Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.

Analysts currently set an average price target of 2 391,26 JPY for the Sysmex stock (median: 2 320,50 JPY), implying +24,6 % versus the latest price. The consensus is based on 21 analyst ratings.

Sysmex Analitikų tikslinės kainos 2026

21 analysts currently rate the Sysmex stock: 16 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sysmex to generate revenue of 498,17 mlrd. JPY and earnings per share of 64,06 JPY.

Sysmex Analitikų tikslinės kainos 2026

Converted at the current exchange rate, the Sysmex share trades at 10,26 EUR (1 888,50 JPY).

The Sysmex share (6869.T) is listed on 4 stock exchanges, including: Frankfurt (0YX.F), München (0YX.MU).

Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.

tikėtina pelnas Sysmex yra 498,17 mlrd. JPY. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.

tikėtina grynasis pelnas Sysmex yra 39,94 mlrd. JPY. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.

Kainų ir nuomos santykis (KGV) Sysmex šiuo metu yra 29,48. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Sysmex akcijos vertę.

Kainų ir pardavimų santykis (KUV) Sysmex šiuo metu yra 2,36. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Sysmex akcijos įvertinimo metrika.

Eulerpool kokybės balas Sysmex yra 8/10.

Sysmex ISIN yra JP3351100007. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.

Sysmex WKN yra 897966. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.

Sysmex prekybos žymė yra 6869.T. Ši biržos žymė naudojama Sysmex akcijoms prekiauti biržoje.

Per pastaruosius 12 mėnesių Sysmex mokėjo dividendus 35,00 JPY dydžio. Tai atitinka maždaug 1,85 % dividendų grąžą. Ateinančiais 12 mėnesiais tikimasi, kad Sysmex mokės dividendus 64,92 JPY dydžio.

Sysmex dabartinis dividendų pajamas yra 1,85 %.

Sysmex moka dividendus, kurie išmokamas , , , mėnesiais.

Sysmex mokėjo dividendus kiekvienais metais per pastaruosius 30 metus.

Ateinančius 12 mėnesių tikimasi dividendų 64,92 JPY dydžio. Tai atitinka 3,44 % dividendų grąžą.

Sysmex priskiriama 'Sveikata' sektoriui.

Norėdami gauti paskutinę Sysmex dividendą iš 18 JPY dydžio, turėjote turėti akciją portfelyje prieš ex-datą .

Paskutinė dividenda buvo išmoketa .

2025 metais Sysmex išmokėjo 28 JPY dividendų.

Sysmex dividendai išmokamas JPY.